Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q1739962> ?p ?o }
Showing triples 1 to 38 of
38
with 100 triples per page.
- Q1739962 subject Q10137627.
- Q1739962 subject Q8934832.
- Q1739962 abstract "Oncotype DX, is a commercial diagnostic test that estimates the likelihood of disease recurrence in women with early-stage hormone estrogen receptor (ER) positive only breast cancer (prognostic significance). There is emerging evidence that such tests may also provide information about the likely benefit from chemotherapy (predictive significance).Oncotype DX analyzes a panel of 21 genes within a tumor to determine a Recurrence Score. The Recurrence Score is a number between 0 and 100 that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis, though the score is not validated, though the buckets of Low, Intermediate or High Risk are when the patient receives / abides to 5 years of Tamoxifen. With this information, it may be possible for doctors and patients to make more informed decisions about breast cancer treatment options. Oncotype DX is performed by Genomic Health in its CLIA-certified, CAP-accredited reference laboratory.The test was initially developed for women with early-stage invasive breast cancer with ER+ cancers whose lymph nodes do not contain tumor (node-negative). Typically in these cases, treatment with anti-hormonal therapy, such as tamoxifen or aromatase inhibitors, is planned, and the test can help define whether chemotherapy should or should not be added to that anti-hormone treatment.".
- Q1739962 wikiPageExternalLink www.genomichealth.com.
- Q1739962 wikiPageExternalLink IsOncotypeRight.aspx.
- Q1739962 wikiPageExternalLink Breast.aspx.
- Q1739962 wikiPageExternalLink IsOncotypeRight.aspx.
- Q1739962 wikiPageWikiLink Q10137627.
- Q1739962 wikiPageWikiLink Q12856785.
- Q1739962 wikiPageWikiLink Q128581.
- Q1739962 wikiPageWikiLink Q14763023.
- Q1739962 wikiPageWikiLink Q14863436.
- Q1739962 wikiPageWikiLink Q14872994.
- Q1739962 wikiPageWikiLink Q14877486.
- Q1739962 wikiPageWikiLink Q14886047.
- Q1739962 wikiPageWikiLink Q14905704.
- Q1739962 wikiPageWikiLink Q14907908.
- Q1739962 wikiPageWikiLink Q17837016.
- Q1739962 wikiPageWikiLink Q18021139.
- Q1739962 wikiPageWikiLink Q18026580.
- Q1739962 wikiPageWikiLink Q18029202.
- Q1739962 wikiPageWikiLink Q18029703.
- Q1739962 wikiPageWikiLink Q2072214.
- Q1739962 wikiPageWikiLink Q3040305.
- Q1739962 wikiPageWikiLink Q4035584.
- Q1739962 wikiPageWikiLink Q412178.
- Q1739962 wikiPageWikiLink Q416496.
- Q1739962 wikiPageWikiLink Q4959789.
- Q1739962 wikiPageWikiLink Q5133770.
- Q1739962 wikiPageWikiLink Q6963969.
- Q1739962 wikiPageWikiLink Q7092091.
- Q1739962 wikiPageWikiLink Q7092137.
- Q1739962 wikiPageWikiLink Q7170583.
- Q1739962 wikiPageWikiLink Q8934832.
- Q1739962 wikiPageWikiLink Q974135.
- Q1739962 comment "Oncotype DX, is a commercial diagnostic test that estimates the likelihood of disease recurrence in women with early-stage hormone estrogen receptor (ER) positive only breast cancer (prognostic significance). There is emerging evidence that such tests may also provide information about the likely benefit from chemotherapy (predictive significance).Oncotype DX analyzes a panel of 21 genes within a tumor to determine a Recurrence Score.".
- Q1739962 label "Oncotype DX".
- Q1739962 homepage Breast.aspx.